{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T07:12:40Z","timestamp":1792566760030,"version":"4.5.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1097\/mao.0b013e3181eb328a","type":"journal-article","created":{"date-parts":[[2010,8,26]],"date-time":"2010-08-26T07:54:14Z","timestamp":1282809254000},"page":"1135-1143","source":"Crossref","is-referenced-by-count":100,"title":["Erlotinib for Progressive Vestibular Schwannoma in Neurofibromatosis 2 Patients"],"prefix":"10.1097","volume":"31","author":[{"given":"Scott R.","family":"Plotkin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Halpin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"McKenna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay S.","family":"Loeffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy T.","family":"Batchelor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred G.","family":"Barker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-21-20210212","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/00129492-200501000-00016","article-title":"Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought.","volume":"26","author":"Evans","year":"2005","journal-title":"Otol Neurotol"},{"key":"R4-21-20210212","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ijrobp.2005.01.055","article-title":"Management of acoustic neuromas with fractionated stereotactic radiotherapy (FSRT): long-term results in 106 patients treated in a single institution.","volume":"63","author":"Combs","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R5-21-20210212","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1097\/00006123-199704000-00007","article-title":"Management of vestibular schwannomas (acoustic neuromas): auditory and facial nerve function after resection of 120 vestibular schwannomas in patients with neurofibromatosis 2.","volume":"40","author":"Samii","year":"1997","journal-title":"Neurosurgery"},{"key":"R10-21-20210212","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1128\/MCB.01139-07","article-title":"Localization to the cortical cytoskeleton is necessary for Nf2\/merlin-dependent epidermal growth factor receptor silencing.","volume":"28","author":"Cole","year":"2008","journal-title":"Mol Cell Biol"},{"key":"R11-21-20210212","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1083\/jcb.200703010","article-title":"Contact-dependent inhibition of EGFR signaling by Nf2\/Merlin.","volume":"177","author":"Curto","year":"2007","journal-title":"J Cell Biol"},{"key":"R12-21-20210212","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/mao.0b013e31815d4429","article-title":"ErbB and Nrg: potential molecular targets for vestibular schwannoma pharmacotherapy.","volume":"29","author":"Doherty","year":"2008","journal-title":"Otol Neurotol"},{"key":"R13-21-20210212","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/00005537-199604000-00012","article-title":"Epidermal growth factor receptor expression by acoustic neuromas.","volume":"106","author":"Sturgis","year":"1996","journal-title":"Laryngoscope"},{"key":"R14-21-20210212","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1097\/00129492-200409000-00024","article-title":"Correlation of growth factor receptor expression with clinical growth in vestibular schwannomas.","volume":"25","author":"O'Reilly","year":"2004","journal-title":"Otol Neurotol"},{"key":"R15-21-20210212","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/01.jnen.0000199575.93794.2f","article-title":"Neuregulin growth factors and their ErbB receptors form a potential signaling network for schwannoma tumorigenesis.","volume":"65","author":"Stonecypher","year":"2006","journal-title":"J Neuropathol Exp Neurol"},{"key":"R17-21-20210212","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.anndiagpath.2006.09.007","article-title":"Epidermal growth factor receptor is not amplified in schwannomas.","volume":"11","author":"Prayson","year":"2007","journal-title":"Ann Diagn Pathol"},{"key":"R20-21-20210212","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00280-007-0616-3","article-title":"The plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite (OSI-420) after intravenous administration of erlotinib in non-human primates.","volume":"62","author":"Meany","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"R25-21-20210212","doi-asserted-by":"crossref","first-page":"39","DOI":"10.7326\/0003-4819-113-1-39","article-title":"NIH conference. Neurofibromatosis 1 (Recklinghausen disease) and neurofibromatosis 2 (bilateral acoustic neurofibromatosis). An update.","volume":"113","author":"Mulvihill","year":"1990","journal-title":"Ann Intern Med"},{"key":"R27-21-20210212","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0194-5998(95)70100-1","article-title":"New and revised reporting guidelines from the Committee on Hearing and Equilibrium. American Academy of Otolaryngology-Head and Neck Surgery Foundation, Inc.","volume":"113","author":"Monsell","year":"1995","journal-title":"Otolaryngol Head Neck Surg"},{"key":"R28-21-20210212","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1044\/jshd.1703.321","article-title":"Development of materials for speech audiometry.","volume":"17","author":"Hirsch","year":"1952","journal-title":"J Speech Hear Disord"},{"key":"R30-21-20210212","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.1990.8.7.1277","article-title":"Response criteria for phase II studies of supratentorial malignant glioma.","volume":"8","author":"Macdonald","year":"1990","journal-title":"J Clin Oncol"},{"key":"R31-21-20210212","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1044\/jshr.2103.507","article-title":"Speech-discrimination scores modeled as a binomial variable.","volume":"21","author":"Thornton","year":"1978","journal-title":"J Speech Hear Res"},{"key":"R32-21-20210212","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/00129492-200601000-00020","article-title":"Using audiometric thresholds and word recognition in a treatment study.","volume":"27","author":"Halpin","year":"2006","journal-title":"Otol Neurotol"},{"key":"R33-21-20210212","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0194-5998(95)70101-X","article-title":"Guidelines for the evaluation of hearing preservation in acoustic neuroma (vestibular schwannoma). American Academy of Otolaryngology-Head and Neck Surgery Foundation, Inc.","volume":"113","year":"1995","journal-title":"Otolaryngol Head Neck Surg"},{"key":"R34-21-20210212","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/ncponc1157","article-title":"Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy.","volume":"5","author":"Plotkin","year":"2008","journal-title":"Nat Clin Pract Oncol"},{"key":"R36-21-20210212","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1200\/JCO.2007.15.3387","article-title":"Bilateral eardrum perforation after long-term treatment with erlotinib.","volume":"26","author":"Lee","year":"2008","journal-title":"J Clin Oncol"},{"key":"R37-21-20210212","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1200\/JCO.2008.16.9391","article-title":"Trichomegaly of the eyelashes after lung cancer treatment with the epidermal growth factor receptor inhibitor erlotinib.","volume":"26","author":"Braiteh","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["Otology & Neurotology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MAO.0b013e3181eb328a","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:37:37Z","timestamp":1786041457000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00129492-201009000-00021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/mao.0b013e3181eb328a","relation":{},"ISSN":["1531-7129"],"issn-type":[{"value":"1531-7129","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}